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Abstract: Gliomas have poor prognosis no matter the treatment applied, remaining an unmet clinical
need. As background for a substantial change in this situation, this review will focus on the following
points: (i) the steady progress in establishing the role of molecular chaperones in carcinogenesis;
(ii) the recent advances in the knowledge of miRNAs in regulating gene expression, including genes
involved in carcinogenesis and genes encoding chaperones; and (iii) the findings about exosomes and
their cargo released by tumor cells. We would like to trigger a discussion about the involvement of
exosomal chaperones and miRNAs in gliomagenesis. Chaperones may be either targets for therapy,
due to their tumor-promoting activity, or therapeutic agents, due to their antitumor growth activity.
Thus, chaperones may well represent a Janus-faced approach against tumors. This review focuses on
extracellular chaperones as part of exosomes’ cargo, because of their potential as a new tool for the
diagnosis and management of gliomas. Moreover, since exosomes transport chaperones and miRNAs
(the latter possibly related to chaperone gene expression in the recipient cell), and probably deliver
their cargo in the recipient cells, a new area of investigation is now open, which is bound to generate
significant advances in the understanding and treatment of gliomas.
Keywords: gliomas; molecular chaperones; Hsps (Heat shock proteins); Hsp60; miRNA; exosomes;
extracellular vesicles; theranostic tools
1. Introduction
The effective treatment of brain tumors, including gliomas, sadly remains an unmet clinical
need. The prognosis is poor even after surgical resection followed by post-operatory chemo-
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and radiotherapies [1]. It is, therefore, cogent to find groundbreaking treatments. Three recent
developments may provide an innovative point of view regarding brain malignancies, opening a novel
vision for development of treatment strategies. These new advances are (i) the discovery that molecular
chaperones can be determinant factors in the process of tumorigenesis; (ii) the elucidation of the role of
miRNAs in gene regulation and determination of protein quantities, including molecular chaperones,
in the various cell compartments; and (iii) the increasing understanding and characterization of
exosomes, particularly in what refers to their release by tumor cells, contents including chaperones and
miRNA, and ability to travel and interact with target cells near their origin or far. This new approach
is supported by three main pillars: chaperones, Hsp60-related miRNAs, and exosomes, specifically
those released by brain gliomas and distributed over the whole body.
The purpose of this article is to take advantage of these three major scientific advances by calling
attention to them, with the purpose of stimulating the investigation in this field and opening our
minds with regard to this new platform for studying and managing gliomas.
As an attractive challenge for the future, we evaluate the possibility to elucidate the role of
extracellular chaperones or related miRNAs in brain tumors, to use them as “theranostic tools”.
The complete elucidation of these factors as cancer biomarkers has potential advantages, since
it should allow the standardization of quantitative tests, with high sensitivity and relatively easy
application [2–4].
2. Gliomagenesis Overview and Clinical and Histopathological Classifications of Gliomas
Glial cells, or neuroglia, are a heterogeneous cellular compartment of the nervous tissue associated
with neurons and have various roles in the central and peripheral nervous systems (CNS and PNS,
respectively). These cells are more numerous than neurons and are functionally distinct from them,
since they are involved in the maintenance of neuronal homeostatic balance and myelination, providing
structural support and protection for neurons. Furthermore, during embryonic development, glial cells
regulate the differentiation and neuronal survival. In the CNS, glial cells are variable in number and in
type, including two main groups: macroglia and microglia. The first group includes the larger types of
glial cells originating in the neural plate represented by astrocytes and oligodendroglia, whereas the
second group includes smaller types of cells originating in the mesoderm. In the PNS, glial cells are
represented by (i) the Schwann cells that develop from the neural crest cells that migrate away from
the neural tube; and (ii) satellite cells that appear postnatally.
Until the discovery of neural stem cells (NSCs) in the CNS [5], it was assumed that glial cells were
the only ones endowed with the capacity to divide and, consequently, the histological classification
of brain tumors was based on glial cells features. In fact, gliomas display histological similarities to
glial cells, including astrocytes and oligodendrocytes and, therefore, they are classified as astrocytoma,
oligodendroglioma, or oligoastrocytoma. More than half of gliomas are glioblastoma multiforme
(GBM; World Health Organization, WHO grade IV astrocytoma) [6,7].
Gliomas and other neuroepithelial tumors constitute 49% of primary brain tumors, while
meningiomas are the next most frequent histologic type (27%). Brain metastases affect 9% to 17% of
cancer patients; this frequency is proportionate to the relative cardiac output to the brain.
The worldwide incidence rate is of 14:100,000 person-years for all gliomas [8]. In the United
States, it was estimated to be 3:100,000, with more than 10,000 cases being diagnosed annually.
GBM constitutes 45.2% of all malignant CNS tumors, 80% of all primary malignant CNS tumors,
and approximately 54.4% of all malignant gliomas. Mean age at diagnosis is 64 years, and it is
1.5 times more common in men than in women and 2 times more common in whites compared to
blacks [1]. The incidence has increased slightly over the past 20 years, mostly due to improved
radiologic diagnosis and increase in life span of men and women [9].
Recent genetic studies have identified a number of recurrent chromosomal abnormalities and
genetic alterations in malignant gliomas, particularly in GBM [10].
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The main biological processes in gliomagenesis are extracellular matrix (ECM) remodellng
and epithelial–mesenchymal transition (EMT). Tumor cell growth and invasion are linked to ECM
remodeling, involving proteolysis. Physiologically, the basement membrane (BM) separates epithelial
cells from the ECM preventing their interaction with the microenvironment. Destabilized BM allows
contact between epithelial cells and various signaling ECM proteins [11]. Expression of mesenchymal
cytoskeletal proteins and deposition of ECM proteins promote the migratory potential of glioma
cells by activating integrin and signaling pathways. These changes activate the invasiveness and
migratory potential of glioma cells, leading to poor prognosis with evasion from treatment agents and
establishment of resistance to therapeutics [12].
One of the major challenges in glioma treatment is the migratory potential of glioma cells
breaching into the blood–brain barrier (BBB)-protected areas of the brain. Hence, unravelling the
migration mechanisms has always been of great importance in glioma research [13].
The major players contributing to glioma cell dissemination are ECM degradation through matrix
metalloproteases (MMPs), intracellular cytoskeletal rearrangements, and stimuli by chemoattractants.
The MMPs mainly aid in degrading the basement membrane along with ECM. During EMT, MMPs
secreted by glioma and stromal cells facilitate ECM remodeling and invasiveness through ECM
degradation, promoting migration due to release of growth factors embedded within the ECM for
activation of signal transduction cascades. The levels of MMPs are correlated with histological grading
of gliomas [13].
Clinically, patients with GBM may present with headaches, focal neurologic deficits, confusion,
memory loss, personality changes, and seizures. Diagnosis and response to treatment are and
monitored by magnetic resonance imaging (MRI) and the use of adjunct technology, such as functional
MRI, diffusion-weighted imaging (DWI), diffusion tensor imaging (DTI), dynamic contrast-enhanced
MRI, perfusion imaging, magnetic resonance spectroscopy (MRS), and positron-emission tomography
(PET) [14].
Currently, maximum safe optimal surgical resection, followed by partial brain radiotherapy with
concurrent temozolomide, and subsequent continuation of temozolomide for 6 cycles, is considered
the standard treatment modality. However, the overall survival for GBM patients is only around
9–12 months, and the overall 5-year survival rate is less than 5%. In this context, the future direction in
GBM management should include the “molecular approach”, in order to achieve strictly pertinent
selection of patients and make the therapeutic protocols personalized and more appropriate.
3. Molecular Chaperones: Locales of Residence, Functions, and Roles during Tumorigenesis
Molecular chaperones, many of which are heat shock proteins (Hsps), are an important class of
molecules with various functions, intra- and extracellularly. Not all Hsps are chaperones, but the terms
chaperone and Hsp are used interchangeably, even if strictly they are not synonyms.
These molecules, for the most part conserved during evolution, are involved in the maintenance of
protein homeostasis by assisting in the folding of client polypeptides, refolding of partially denatured
proteins, and degradation of proteins damaged beyond repair (references in [15]). Chaperones
also participate in protein translocation across membranes. One might say that chaperonology is
a scientific discipline that studies molecular chaperones and the pathological conditions in which
chaperones may become pathological factors, known as chaperonopathies [16]. Chaperone therapy,
or chaperonotherapy, involves the use of chaperones in the treatment of chaperonopathies [17,18].
A practically useful classification of chaperones groups them by molecular weight as follows: super
heavy, 100, 90, 70, 60, 40, small Hsp (sHsp), including chaperones within the following ranges in kDa:
100 or higher, 81–99, 65–80, 55–64, 35–54, and 34 or lower, respectively [19,20].
The Hsps were initially described as a group of intracellular proteins whose genes are induced
by heat shock, as well as by other stressors [21]. Expression of Hsps occurs in response to a wide
variety of stressors, such as hyperthermia, hypoxia, ischemia, heavy metal or ethanol exposure,
and infections [13]. Most Hsp chaperones are involved in various physiological mechanisms
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in normal cells, such as DNA replication and gene expression regulation [22,23]. Furthermore,
molecular chaperones have other roles, such as participation in immune system regulation [18,24], cell
differentiation [25] and apoptosis, and carcinogenesis, including GBM [15,26]. The levels of some Hsps
are elevated in various types of cancer, which usually indicates poor prognosis in terms of survival
and response to therapy [21]. Numerous studies have shown that Hsps are involved in malignant
transformation, metastasization, and appearance of multidrug-resistance [26,27]. In addition, elevated
levels of intracellular Hsps can protect malignant cells against therapy-induced apoptosis [22,26].
Chaperones have canonical and non-canonical (moonlighting) functions, with the former
pertaining to the maintenance of protein homeostasis and the latter pertaining to other aspects of
cellular and organismal physiology unrelated to protein homeostasis. Chaperones are components
of the chaperoning system (CS) of an organism together with co-chaperones, chaperone co-factors,
and chaperone receptors and interactors [19,20]. The main partners of the chaperoning system in
the maintenance of protein homeostasis (i.e., the canonical functions) are the ubiquitin–proteasome
system (UPS) and the chaperone-mediated autophagy (CMA) machinery, whereas the major partner
for non-canonical functions is the immune system (IS). When the interaction between the CS and the
IS is altered (e.g., chaperone mutation, or overexpression, or post-translational modification) chronic
inflammatory and autoimmune disorders, and cancer progression and metastasization, may occur.
4. miRNAs: Intracellular Localization, Functions, and Roles during Tumorigenesis
The realization that tumorigenic mechanisms develop because of alterations at various levels of
the gene expression regulation, including chaperone genes, opened new avenues to study the role of
non-coding nucleic acid molecules in cancer.
There is a large number of non-coding (i.e., they do not encode proteins) nucleic acids which
have different structures, and which act as key regulators of gene expression in many different cellular
pathways and locales. About 98–99% of the human genome encodes molecules considered for a long
time as “dark matter” whose biological significance has long been debated. Nevertheless, in the
last twenty years, non-coding RNA (nc-RNA) has been widely studied, and its complex role in
pathophysiological mechanisms is now better understood [28–31].
The term “non-coding RNAs” describes a large group of RNAs that contains subgroups with
different functions. They are classified based on the molecular length, as follows: non-coding RNAs
that have more than 200 nucleotides in length are “long” non-coding RNAs (lncRNA), while those that
have less than 200 nucleotides are the “small” non-coding RNAs (sncRNAs). lncRNAs appear to be
epigenetic regulators affecting, at various levels, protein-coding gene expression. sncRNAs seem to
be involved in many, if not all key cellular activities, including development and differentiation, and
transcriptional and post-transcriptional gene silencing, all functions that seem to be determined by
the subcellular localization [32]. sncRNAs include various different small RNAs, such as microRNAs
(miRNAs), small nucleolar RNAs (snoRNAs), and piwi-interacting RNAs (piRNAs) [33]. miRNAs
recognize target RNAs and play a key role in modulating gene expression in a sequence-specific
manner. A number of studies on miRNA expression profiles and on inhibition of pathogenic miRNAs
have been at the basis of efforts for developing new tools for diagnosis and assessing prognosis and
response to treatment and also novel therapeutic agents and strategies [34,35].
Most microRNAs are transcribed by RNA polymerase II under the control of various transcription
factors, as long transcripts characterized by a complex hairpin structure (pri-miRNA), and are
processed in the nucleus by a RNase III, named Drosha, to generate the microRNAs precursors
(pre-miRNA) with a length of 70–100 nucleotides. These precursors are transferred from the
nucleus to the cytoplasm, in which they undergo further maturation mediated by another RNase III
(Dicer), generating a double-stranded RNA (dsRNA) of 22 nucleotides. This dsRNA is subsequently
incorporated in a protein complex, known as RISC (RNA-induced silencing complex), which promotes
the formation of single-stranded mature molecules. In the RISC protein complex, mature miRNAs are
able to pair with complementary sequences present in the 3′-UTR region of mRNAs and to regulate
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gene expression at the post-transcriptional level. miRNAs may induce mRNA degradation or blockage
of translation without mRNA degradation, depending on the complementarity of the bases between
the miRNA and its target site [36].
The finding that the miRNA miR-15a and miR-16a gene sequences were deleted or downregulated
in the majority of B-cell chronic lymphocytic leukaemias (B-CLL) [37], was one of the first indications
of the involvement of miRNAs in human tumorigenesis. As a consequence, many studies were carried
out on the correlation between genomic position of miRNA genes and the cancer-associated genomic
regions, accompanied by miRNAs overexpression/downregulation that resulted in transcriptional
control and epigenetic changes and in defects in the miRNA biogenesis machinery [38–40].
The mechanism of miRNAs dysregulation in cancer involves amplification or deletion of their
genes [37,39], and abnormal expression of transcriptional factors that regulate miRNAs expression [41].
Other factors that generate miRNAs dysregulation leading to tumorigenesis are epigenetic alterations,
i.e., aberrant DNA methylation and histone acetylation of miRNAs genes [42], and defects in enzymes
involved in the miRNAs maturation steps [43].
The identification of different expression profiles of miRNAs in the neoplastic tissue compared
with its normal counterpart supports the hypothesis of a probable involvement of miRNAs in tumor
development and progression, including evasion of apoptosis, and also induction of cell migration,
epithelial–mesenchymal transition (EMT), and angiogenesis [44,45]. The expression of miRNAs, in
different tumor-cell types (lung, breast, stomach, prostate, colon, and pancreas), was found distinctive
of tumor type, suggesting a definite role of miRNA in human tumorigenesis and indicating that
miRNA expression is a signature of the tumor cell that could be used for tumor classification, diagnosis,
and assessing prognosis [46].
Little is known about the cellular sites where miRNA-mediated post-transcriptional regulation
occurs. It has been shown that Argonaute (AGO) protein–miRNA complex is present in cellular
organelles, including endoplasmic reticulum (ER), Golgi apparatus, lysosomes, and endosomes [47–49].
miRNAs have been found in different cellular fractions, and in the extracellular environment, into
which they would be secreted by passive and/or active mechanisms, for example, by loading them
onto extracellular vesicles, such as exosomes [50]. In the passive mechanism, miRNA secretion would
be driven by the natural affinity of the nucleotide sequences with lipid rafts [51], whereas the active
mechanisms (regulated secretion) would be due to translocation into microvesicles that act as signal
transporters and mediate long-range cell–cell communication [52].
Numerous studies have shown the presence of miRNAs within the exosomes, and that the
variation of the intracellular amounts of individual miRNAs was reflected within the exosomes [53].
It could very well be that miRNAs released with the exosomes from cancer cells are able to alter
gene expression in surrounding and far away tissues, and thereby contribute to the progression of
tumors [54]. Currently, the mechanism of miRNA sorting into the exosomes is still poorly understood.
5. Exosomes: Nanovectors for Extracellular Chaperones and miRNAs
Exosomes are extracellular nanovesicles of 20–100 nm in diameter, of endosomal origin, that
are secreted by virtually all cell types, probably to exchange information and to maintain cellular
homeostasis, for example, in response to pathogens. Exosomes play an important role in cell–cell
communication, different from that occurring by the classical pathway involving direct cell–cell contact
and secretion of soluble factors [55,56].
It was initially thought that exosomes could be part of a mechanism for shedding the cytoplasm
content during maturation of reticulocytes [57]. Several studies provided further support to show that
exosomes are also present in body fluids, such as blood, urine, breast milk, saliva, and bronchoalveolar
lavage, and cerebrospinal, ascitic, and amniotic fluids [56]. Clinical trials have shown that exosomes
can be characterized and quantified in the plasma of healthy subjects and of patients with tumors of
different histology [4,58], using different techniques, including immunocapture-based Enzyme Linked
Immunosorbent Assay (ELISA), Nanoparticle tracking analysis (NTA), and nanoscale flow cytometry.
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This approach allowed to compare old and new disease biomarkers and also to quantify the plasmatic
levels of exosomes, providing new insights on this issue. This was an important contribution, since
chronic disease conditions may be characterized by higher plasmatic exosome levels, as compared
to both healthy and other diseased controls [4,58], suggesting that, at least in tumor patients, higher
plasmatic levels of exosomes may represent a marker of disease, per se [59].
Exosomes are released into the extracellular space after the merging of late endosomes with
the cell membrane. This release is preceded by early endosomes becoming part of multivesicular
bodies (MVBs), which undergo a maturation process that determines a gradual change in molecular
composition of the vesicles (intraluminal vesicles, ILVs). The vesicles in the MVBs merge with the
lysosomes during this maturation process, which causes degradation of their contents (e.g., in the
case of receptors), or constitutes a temporary storage compartment, or they may blend with the
plasma membrane, releasing exosomes. In brief, MVBs merge with the plasma membrane, resulting in
exocytosis of the vesicles contained in MVBs, i.e., exosomes [58,59].
Exosomes have cell type-specific contents. Numerous studies are being conducted to elucidate
the contents of exosomes with the purpose of determining their functions and, ultimately, use them in
therapeutics, for example, as vehicles for drug or chaperone delivery [60,61]. Various functions have
been attributed to exosomes, depending on the source cell and their contents. For instance, exosomes
are involved in cell-to-cell information transfer [62], inflammation [63], coagulation [64], stem cell
activation [65], programmed cell death [66], and the immune response [63].
It seems plausible that the exosomes’ composition depends on the parental cells contents,
including proteins; lipids; nucleic acids, such as DNA and non-coding RNA (e.g., ribosomal RNA
(rRNA), and miRNAs).
Different sets of proteins are found in exosomes, some strictly involved in vesicle trafficking,
such as cell surface receptors; others pertaining to the endocytic pathway (i.e., endosomal sorting
complex required for transport, ESCRT, such as Alix; tumor susceptibility gene 101, TSG101;
integrin; and tetraspanins); and still other proteins involved in long distance communication, such as
cytokines [67], hormones [68], growth and transcription factors [69], and Hsps [68,69].
Hsp60, Hsp70, and Hsp90 are secreted by cancerous cells via the exosome pathway [63–65].
Exosomal Hsps may have opposite effects: immunosuppressing or immunostimulating. These
different effects depend on the interaction between exosomal Hsps and cells of the immune system.
For instance, Hsp60, Hsp70, and Hsp90α are actively secreted via the exosomal pathway, and
mediate immunomodulatory effects and immune response against cancer cells [70,71]. Extracellular
Hsp70 activates macrophages [72–74] and natural killer cells [75,76], while Hsp90α, when released by
invasive cancer cells via exosomes, enhances cancer cell migration [77].
Our research group has provided one of the first pieces of evidence that Hsp60 is present in
exosomes, including the mechanism by which the chaperonin is loaded onto exosomes, and its location
in them [70,78]. Under normal conditions, Hsp60 acts as a molecular chaperone intracellularly but, on
the other hand, in several pathological states it is overexpressed and is released by both the classical
pathway and via exosomes. In heart failure, Hsp60 is secreted by cardiomyocytes, and its presence
in the serum correlates with disease severity and cardiovascular risk [76,78]. Hsp60 is released by
adult cardiomyocytes via the exosome pathway in both the basal state and following mild stress [79].
Fibrosarcoma cells release Hsp60 through the conventional endoplasmic reticulum–Golgi protein
transport pathway [80]. In in vivo studies, we showed that the exosomal Hsp60 levels in the plasma
of patients before colon cancer surgery were significantly higher than in the exosomes from the
same patients after tumor ablation [71]. Hsp60 exportation by exosomes, which would undergo
post-translational modifications [81], points to roles of this chaperonin in inflammation, immune
system modulation, and regulation of tumor microenvironment and growth. Therefore, exosomal
Hsp60 may contribute to the regulation of gene expression in target cells at distant sites (reviewed
in [2]).
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The presence of mRNA [82] and miRNA [83] in exosomes suggest regulatory activity on gene
expression in recipient and donor cells, and horizontal transfer of genetic information.
The mechanism by which miRNAs are loaded on to exosomes remains unclear. It is debated
whether miRNA molecules are specifically charged onto exosomes, or incorporated passively, as
a result of mutual affinity between repeated RNA sequences and lipid rafts. As is known, during
maturation, the miRNA–protein complex (miRISC) is incorporated in late endosomes and subsequently
in exosomes, but certain exosomal miRNAs are independent of miRISC [47]. On the other hand, specific
sequences present in certain miRNAs may guide their incorporation into exosomes [84], a possibility
supported by the finding that exosomes from diverse sources, including several human body fluids,
contain only one copy of a given abundant miRNA, because many more copies would be expected from
random sampling. This suggests a tightly regulated sorting mechanism that has yet to be elucidated.
The number of molecules that are loaded within exosomes and whether it can actually determine
a modulation of gene expression in the recipient cells are still under scrutiny. In conclusion, it has
been shown by various researchers [84–87] that specific mechanisms for miRNAs sorting into secreted
vesicles do exist, and which molecules are actually sorted depends on the translational status in
the source cells. Therefore, one can speculate that specific miRNAs encapsulated in exosomes can
educate the recipient cells, a possibility that, if proven, will represent an important pathophysiologic
event in long distance cell–cell communication. In this regard, it has to be emphasized that miRNAs
are preserved in a stable form inside the exosome, in which they are protected from endogenous
RNase activity.
6. Chaperones, miRNAs, and Exosomes as Novel Molecular Target to Be Explored for Diagnosis
and Prognosis Assessment of Gliomas
Since the main biological processes in gliomagenesis are extracellular matrix (ECM) remodeling
and epithelial–mesenchymal transition (EMT), efforts have been directed to elucidate the molecular
mechanisms involved. The dysregulation of the activity of glioma cells can induce in them the capacity
to release different class of molecules, with effect on the surrounding environment. This release may
be mediated by exosomes, which induce modifications of the recipient cell phenotype and remodeling
of ECM, causing cancer propagation [88].
It is well established that brain-derived exosomes can cross the blood–brain barrier (BBB) [89–92],
probably by a mechanism involving their surface epitopes [93,94], and so they can be found in plasma.
Tumor cells produces exosomes in markedly altered numbers and composition, although nowadays,
their functions in circulation still remains unclear, but it is believed that they influence tumor growth
and progression [59]. Therefore, in normal and pathological conditions, the nervous cells release, via
the exosomal pathway, several bioactive molecules, participating in long-distance communication
(Figure 1). The analysis of exosome contents could be a possible way for monitoring the changes
occurring in brain, offering new promising approach for biomarkers discovery and for identifying
novel targets for treatment.
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modulation of the immune system and in the regulation of gene expression in the target cells, and 
would modify the tumor microenvironment, ultimately favoring tumor dissemination, for instance, 
through the blood–brain barrier. The challenge consists in manipulating these elements to use them 
as therapeutic agents. Icons are explained in the bottom right inset. 
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to treatment response [95]. The proteins are involved in pathways for remodeling of ECM, biological 
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Figure 1. Chaperones and exosomes from glioblastoma multiforme (GBM) cells are central and
conspicuous players in patients and constitute attractive targets for therapeutics along with pertinent
miRNAs. The figure presents the elements that provide the foundations for research toward the
development of new therapies and summarizes the main thesis of this review, as a proposal for future
research, since various points are still under scrutiny. GBM cells differentially express various Hsps,
which play pivotal roles in chemoresistance, apoptosis escape, invasiveness, and cell migration (shown
in the top right inset). Hsps also occur extracellularly, free or in exosomes released by GBM cells
carrying these proteins and miRNAs. Exosomes with their cargo would participate in the modulation
of the immune system and in the regulation of gene expression in the target cells, and would modify
the tumor microenvironment, ultimately favoring tumor dissemination, for instance, through the
blood–brain barrier. The challenge consists in manipulating these elements to use them as therapeutic
agents. Icons are explained in the bottom right inset.
Extracellular vesicles isolated from GBM cells carry a variety of proteins, nucleic acids, lipids, and
other metabolites, that represent accessible biomarkers for diagnosis and for assessing response to
treatment response [95]. The proteins are involved in pathways for remodeling of ECM, biological
adhesion, developmental processes, and progression of inflammation, leading to cancer growth [95].
Among the proteins that were detected in exosomes produced from glioma cells, we can mention
the coatomer protein complex subunit; collagen type VI; myosin heavy chain 1; keratin; annexin
A1, A2, A4, A5, A6, A11; Ras-related protein 10 (Rab10), Rab7a, Rab5c; type I collagen and type VI
alpha 1 collagen; integrins (β1, α3, αV); CD44; and different kinds of tubulins and actinins [96,97].
The surface of exosomes isolated from GBM cells present the specific mutant epidermal growth factor
receptor variant III (EGFRvIII), which is the best known and most specific protein marker for GBM [98].
Although evaluation of EGFRvIII protein levels would be the most direct assessment, availability
of antibody reagents is limited, resulting in the use of nucleic acid techniques for detection [99].
Other studies identified MMP9, TGF(Transforming growth factor)-β, IL(interleukin)-10, and isocitrate
dehydrogenases 1 (IDH1) and 2 (IDH2) as components of extracellular vesicles and exosomes cargo
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produced by GBM cells or isolated from blood [98]. These proteins have not been proposed as specific
markers, since they were found in both cancer and normal cells. Still other proteins, such as Hsps
(Hsp27, Hsp60, Hsp70, Hsp90, Hsp110) have been found [97].
In glioblastoma, as well as in other cancers, Hsps display chaperoning activity to assist various
components of the ECM remodeling machinery, and a positive correlation has emerged between high
expression of Hsps and the triggering of the invasive and metastatic potentials of glioma cells [100].
Poor prognosis and resistance to therapeutics are closely associated with elevated expression of
Hsps in gliomas. Hsps promote cancer growth by stimulating cell proliferation and inhibiting cell
death pathways [101,102]. In glioma cell lines, Hsp27, Hsp70, and Hsp90 play key roles in pathways
involved in survival, invasiveness, and migration [103–107] (Table 1). Furthermore, Hsp60 promotes
glial cell proliferation with the chaperonin being differentially expressed in glioma tissue, which
contrasts with surrounding normal areas [108]. It is likely that extracellular Hsps participate in
immune system stimulation or, on the other hand, they may favor tumor escaping from immune
reaction. Hsp participation in cell-to-cell crosstalk [74,96] is made possible by their being on the
exosome’s surface, and being secreted by both normal and tumor cells [109]. Hence, Hsps may be
important for intercellular cross talk, and when present on the exosome surface, can enhance the
activity of the immune system [2,71,72,110]. Thus, exosomes containing Hsps have high potential
for both diagnostic and therapeutic applications, and may be considered candidates, alone or in
combination with other biomarkers, for use as potential antitumor vaccines or immunotherapeutic
vehicles for targeting malignant cells. Of note, the determination of exosomal Hsp is relatively easy by
high throughput proteomic analysis or by a simple Western blot, involving a non-invasive method
such as the withdrawal of a blood sample.
Table 1. Involvement of molecular chaperones in glioma genesis and pathology.
Main GBM-Related Chaperones 1 Functions Ref.
Hsp27
Phosphorylated Hsp27 at high levels co-localizes with
secreted protein acidic and rich in cysteine (SPARC),
and associates with changes in cell morphology, migration,
and invasion in vitro.
[102]
Hsp27 overexpression is observed in parallel to the
increase in malignancy, as a predictive factor of poor
prognosis for GBM.
[111]
Hsp60 Hsp60 overexpression inhibit tumor cell death orantitumor immune system response. [108]




Hsp60 binds triggering receptor expressed in myeloid cells
2 (TREM2), increasing phagocytic activity in the N9
microglial cell line.
[113]
Hsp70 Hsp70 stabilize the activating transcription factor 5 (ATF5),determining a pro-survival effect in C6 and U87 cells. [104]
Hsp70 overexpression inhibits tumor cell death or
antitumor immune system response. [108]
Hsp90
Hsp90 binds and stabilize its client protein (e.g., PTEN,
p53, and EGFR) to maintain its expression, leading to
aggressive growth in GBM.
[105]
Hsp90 co-localize with ALDH (aldehyde dehydrogenase)
in cancer stem cell sub-population. [107]
Extracellular Hsp90α favors cell migration of glioblastoma
U87 cells. [112]
1 Abbreviations: GBM, glioblastoma multiforme; Cyp, cytochrome P450; PTEN, phosphatase and tensin homolog
(phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase); EGFR, epidermal growth factor receptor.
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Brain tumor tissue studied by Western blot and immunohistochemistry (IHC) showed a marked
increase in the constitutive expression of Hsp27, Hsp90, GRP (glucose regulated proteins) 78 and
75, and Hsc70 (or Hsp70) and the co-chaperone HspBP1 (Hsp70 Binding Protein 1) [112,114,115]
(Table 1). Experimental in vivo tumors grown from glioma cell lines express Hsp27 and Hsp70 at high
levels [103,116]. Hsp27, Hsp60, Hsp70, and Hsp90, namely the Hsps, overexpressed in glioma cells,
can all be released via exosomes [112] (Table 1).
These observations, together with the finding that anticancer agents can cause resistance to
chemo- and radiotherapies [117], encourage us to consider Hsps as targets of an effective strategy for
management of human gliomas.
The role of Hsp60 on gliomagenesis is still poorly understood, although it has been established
that it is differentially expressed in glioblastoma cell lines [118,119] (Table 1). Depletion of Hsp60 in
in vivo models of GBM led to suppression of the intracranial tumor [118].
Hsp60 upregulates various pathways that provide survival benefits to malignant cells, bypassing
apoptosis and/or senescence [81], and probably, the chaperonin regulates the miRNAs pathway,
too. Increase or decrease in the levels of Hsp60 and the pathophysiological significance of these
quantitative variations seem to be dependent on the locale in which the chaperonin resides [120].
Cytosolic Hsp60 has a pro-apoptotic role: it binds pro-caspase 3 allowing its activation in normal
cells [121] but, in tumor cells, Hsp60 does not activate the caspase pathway assuring malignant cell
survival and, thus, contributes to tumorigenesis [122] by playing an antiapoptotic role [123]. It has
been observed that extracellular Hsp60 can mediate apoptosis via its ligand (e.g., Toll-like receptor 4),
causing a pro-survival effect in glial cells [113]. Hsp60 is also involved in microglial activation, leading
to overproliferation under abnormal conditions [124] (Table 1). It has been reported that the presence
of Hsp60 in the surface of astrocytes, which are known to interact continuously with the microglia in
both physiological and pathological conditions, could have a role in the protection of the brain [124].
Surprisingly, this hypothesis appears to be in contrast to the pro-inflammatory role of extracellular
Hsp60, but now it is widely accepted that Hsp60 has multifaceted roles, for instance, depending on its
tissue localization [71]. Moreover, it has been shown that Hsp60 is released by cells, likely through
exosomes, possibly coordinating various functions of the brain cell types [124].
Besides the multiple roles in cell homeostasis regulation, Hsps participate in several tumorigenic
pathways, such as the inhibition of caspase-dependent pathways [125], or through favoring the cell
morphology modification, migration and invasion [103,126], and inducing neoangiogenesis [127]. On
the other hand, Hsp40 has been implicated in contrary effects, because it also induces apoptosis [128].
However the underlying mechanisms are not fully elucidated and, until now, only few inhibitors have
been developed against several Hsps, reporting promising results, but at the initial stage, in other
cancer types [129–132]. Further studies of molecular characterization of Hsps would be needed in order
to use these proteins as therapeutic targets in GBM. It has been observed that the functional significance
of Hsps seems to be dependent on their localization, and it is possible that glioma cells use exosomes
to release Hsps [124] as a means to modulate the immune system and, probably, to release miRNAs
molecules, targeting Hsp gene sequences, for example (Figure 1). This would result in a modulation of
gene expression in the target cells, determining a modification of the tumor microenvironment and
favoring tumor dissemination.
Regarding the regulatory potential of miRNAs in Hsp expression, it has been demonstrated that
miR-628-3p affected migration and apoptosis in lung cancer cells, downregulating Hsp90a protein
expression via a post-transcriptional mechanism [133], and that the oncogene Hsp90B1 is a direct target
of the tumor suppressor miR-223 in a cell model of human osteosarcoma [134]. Likewise, it has been
established that hyperthermia-induced overexpression of Hsp90 was suppressed by miR-27a in human
oral squamous cell carcinoma HSC-4 cells [135]. MiR-142-3p has been indicated as a novel regulator of
Hsp70 expression in triptolide-induced pancreatic cancer cell death [136], and it has been reported
that miR-1/miR-206 suppressed Hsp60 expression, contributing to glucose-mediated apoptosis via
the MEK(extracellular signal-regulated kinase)-1/-2 pathway in cardiomyocytes [137]. Also, miR-382
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contributes to renal tubule-interstitial fibrosis by downregulating Hsp60 expression [138]. Inhibitors
of miR-29a promote apoptosis through upregulation of Hsp60 level and downregulation of Hsp27,
Hsp40, Hsp70, and Hsp90 levels in breast carcinoma MCF-7 cells, suggesting a possible alternative for
current chemotherapy with fewer side effects [139]. These data suggest that cancer cells use Hsps as
an escape mechanism from apoptosis, therefore, their inhibition by modulating miRNAs may provide
a novel antitumor therapy, particularly for gliomas.
7. Potential Therapeutic Applications and Conclusions
The conventional treatment strategy for glioma entails maximal surgical abscission, radiotherapy,
and concomitant/adjuvant chemotherapy [140,141]. Despite contemporary treatments, the prognosis
for GBM patients remains dismal. A number of difficulties confront the physician. For instance,
some brain lesions are not surgically accessible, are genetically and phenotypically heterogeneous,
and may possess acquired resistance to therapeutics because GBM cells are endowed with various
active key oncogenic pathways and effective cytoprotective mechanisms. Over the last years, research
efforts have been aimed to discover genetic alterations or aberrant signaling pathways, in order to
understand the biology of gliomas. Genomic, transcriptomic, and proteomic profiling may unveil
new molecular aspects yet unknown of high-grade gliomas. It is known that molecular chaperones
potentially confer resistance against chemo- and radiotherapies [26,27,142,143] and support glial tumor
growth and invasion [13]. Given their functions, Hsps are able to interact with a wide spectrum of
molecules, playing a cytoprotective role against various types of cellular stress. Under pathological
conditions, Hsp dysregulation could favor cell survival in the face of lethal injuries, leading to
apoptosis inhibition. This phenomenon would be increased in the tumor environment by molecular
effectors, such as miRNAs, which has been shown to have as targets several pathways involved in
GBM [144] and have, as downstream targets, some mRNAs for Hsps or for molecules connected to
Hsp pathways [135,145–148]. miRNAs may also be released by tumor cells, through exosomes for
instance, determining gene expression regulation with both autocrine and paracrine modalities, and
promoting tumor growth in the surrounding tissues. These players constitute a complex molecular
signature that, if fully elucidated, represent an important step towards the definition of biological
markers for brain malignancy and for developing specific treatments for patients.
The search for effective glioma patient stratification based on molecular features could be achieved
by exploiting chaperones or their regulators as therapeutic targets. Anti-GBM vaccines, specific
chaperone inhibition, and drug (natural/synthetic) discovery strategies are some of the most promising
novel theranostic additions in the field of glioma therapy.
There is encouraging potential to enhance the research on molecular chaperones that, in the near
future, could be proposed as novel biomarkers for diagnosis, assessing prognosis and follow-up of
a variety of pathological conditions, or for therapeutic applications (Figure 1).
A major obstacle in glioma treatment is that, on exposure to chemo- and radiotherapies, a number
of patients develop resistance to these therapeutic agents associated with a marked increase in
Hsps [142,143]. It has also been observed in a number of cases that inhibition of Hsps causes regression
of ECM and EMT markers with an increase in cell sensitivity to chemo- and radiotherapies [13]. One
may then infer that molecular chaperone Hsps are involved in conferring chemo/radioresistance to
glioma patients, thus acting as cytoprotectants for cancer cells. It follows that the therapies that act in
conjunction with chaperone inhibitors, negative chaperonotherapy [22], may prove to be an effective
strategy in glioma treatment.
Various novel strategies are being used or are good prospects, such as Hsp vaccines, Hsp inhibitors
in combination with anticancer drugs, Hsps as vaccines on exosome surface, and miRNA technology,
all means with the potential ability to overcome the threat posed by Hsps as cytoprotective of
tumor cells. The addition of such novel approaches to conventional treatment strategies and the
characterization of the mechanisms involved in the Hsps’ influencing ECM and EMT will certainly aid
in glioma management.
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It can be concluded that it would be beneficial to look at the CNS tumors through the chaperone
eye, so to speak, and consider at least some of these tumors to be chaperonopathies by mistake or
collaborationism [17]. In these chaperonopathies, one or more chaperones favor tumor growth, instead
of protecting the organism as they are supposed to do. Therefore, looking at tumors through the
chaperone eye implies that patient examination should include qualitative and quantitative analyses
of Hsps, including those in exosomes, before and after surgery, and other treatments for monitoring
disease evolution and response to treatment [149]. This conduct will provide insights on brain tumors
that will enhance progress in clinical applications of chaperones and exosomes, including their use as
therapeutic agents.
Another promising avenue stems from the fact that cancer-related miRNAs associated with Hsp
genes and pseudogenes have been determined for different cancer type as reported above [139]. Similar
types of characterization of miRNAs, associated to Hsp genes in GBM, could guide diagnosis, and
would aid in the designing of new anti-glioma therapies [121,122].
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